Fritextsökning
Innehållstyper
-
Valves with piezo technology
Efficient control and regulation of gases in medical technology
-
Astra Zeneca’s asthma drug nears approval for sinus inflammation
Astra Zeneca’s drug Tezspire receives positive opinion from the European Medicines Agency (EMA) for the treatment of chronic rhinosinusitis with nasal polyps.
-
Scale Up Your Image Analysis
ZEISS arivis Hub for accelerated analysis and faster results.
-
The dock that “thinks” for itself
The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...
-
Japanese pharma to buy US drugmaker for $2.4 bln
Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.
-
Nanexa develops depot formulation of the diabetes and obesity drug Saxenda
Uppsala-based company Nanexa has signed an agreement with a German contract research company to start a clinical study with a monthly depot of liraglutide. The ...
-
Reliably gripping and turning small parts
The extremely compact rotary gripper module EHMD is the ideal choice in many life science applications where small objects need to be gripped and turned in conf...
-
Are you ready for EMC 2024?
Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.
-
”Information security must become part of the Swedish life science strategy”
Sweden needs knowledge security to stand strong in the global competition, writes Björn Ursing in an opinion article.
-
Exploring Molecular Dynamics with Raster Image Correlation Spectroscopy
Understand how RICS can be used to measure diffusion coefficients.
-
Did you know that not every sphere is really a round sphere?
ZEISS Metrology Expert Tip.
-
Microscopy in Urinalysis: Observe Urine, Detect Abnormalities
Webinar on 18th March 2025, 10 AM - 11 AM CET.
-
A green nursery for biotech rooted in the Scanian soil
Red Glead has established itself as one of Lund’s largest companies in pharmaceutical development. Life Science Sweden went to Skåne and met two of the founders...
-
Rising interest in CRISPR treatments
Treatments using CRISPR technology are emerging as one of the hottest medical trends in the United States – and the FDA is doing its best to promote the development.
-
Webinar: Can AI replace humans in pharmacovigilance?
The webinar will explore how AI can transform pharmacovigilance by enhancing efficiency, reducing errors, and addressing challenges such as software costs, data...
-
Editorial: ”AI that both impresses and frightens”
”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...
-
Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far
Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, ...
-
Forskaren in Hagastaden now inagurated
The real estate company Vectura's life science center in Hagastaden, Forskaren, is now inaugurated. The opening was attended by people from the industry, politi...
-
Clean solutions - Handling viscose substances with precision
Laboratories in the chemical, petrochemical, pharmaceutical and food technology industries are increasingly relying on automation for sample preparation. The Mo...
-
Anna Törner: ”Orphan Designation – the "petite robe noire" of drug development”
It is easy to cling to various regulatory incentives, like orphan designation, and other expedited pathways, without understanding what they truly mean or wheth...
-
From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”
A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...
-
GSK acquires oncology research company
GSK acquires the American biotechnology company Idrx for up to 1.15 billion dollars.
-
Suing the company – for NOT developing a new HIV drug
Was Gilead putting a steady flow of profits from its cash cow ahead of developing a new and safer drug? According to a large number of US HIV patients in a lega...
-
Italian pharmaceutical company buys rights to immunotherapy from Sanofi
Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).
BREAKING